181 related articles for article (PubMed ID: 30361900)
21. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
22. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
[TBL] [Abstract][Full Text] [Related]
23. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
24. Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma.
Guan X; Wang P; Chi J; Zhao S; Wang F
Biochem Biophys Res Commun; 2017 May; 486(4):898-903. PubMed ID: 28342873
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M
Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
[TBL] [Abstract][Full Text] [Related]
26. Association Between BRAF
Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P
Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398
[TBL] [Abstract][Full Text] [Related]
27. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
28. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
29. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
30. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
31. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
[TBL] [Abstract][Full Text] [Related]
32. ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer.
Ma F; Bi L; Yang G; Zhang M; Liu C; Zhao Y; Wang Y; Wang J; Bai Y; Zhang Y
Oncol Rep; 2014 Sep; 32(3):1071-7. PubMed ID: 25017610
[TBL] [Abstract][Full Text] [Related]
33. Key candidate genes associated with BRAF
Yu X; Zhong P; Han Y; Huang Q; Wang J; Jia C; Lv Z
J Cell Physiol; 2019 Dec; 234(12):23369-23378. PubMed ID: 31161615
[TBL] [Abstract][Full Text] [Related]
34. Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.
Zou M; BinHumaid FS; Alzahrani AS; Baitei EY; Al-Mohanna FA; Meyer BF; Shi Y
Clin Endocrinol (Oxf); 2014 Jul; 81(1):109-16. PubMed ID: 24382015
[TBL] [Abstract][Full Text] [Related]
35. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
36. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
[TBL] [Abstract][Full Text] [Related]
37. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
38. LncRNA RGMB-AS1 is activated by E2F1 and promotes cell proliferation and invasion in papillary thyroid carcinoma.
Zhang Z; Li SY; Zhang LB
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1979-1986. PubMed ID: 29687852
[TBL] [Abstract][Full Text] [Related]
39. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
40. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
